14 days Prescribing information Palivizumab powder and solution Synagis (MedImmune) Lifetime cumulative exposure for 14 days Manufacturer Pancuronium bromide injection Pavulon (Gensia/Sicor ...

Sobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain conditional payments. As part of the deal, first announced in August ...

Last year, Sobi bought two AstraZeneca drugs – already-marketed Synagis (palivizumab) for respiratory syncytial virus infections and phase 3 follow-up MEDI8897 – in a deal valued at up to $1.5 ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...